Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Taysha Gene Therapies

Biotech & Life Sciences · Dallas, United States · Founded 2020 · IPO 2020 Unicorn

On a mission to eradicate monogenic CNS disease

Valuation
$1.58B
Market cap · May/2026
Revenue
$9.8M
Latest reported FY
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

20 investors on Taysha Gene Therapies's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage
PBM Capital Group
Nolan Capital
Series B+ 18 investors entered at this stage
Invus
Venrock
Casdin Capital
Acuta Capital Partners
GordonMD Global Investment
Sands Capital Management
B Capital
BlackRock
ArrowMark Partners
Octagon Capital Partners
RA Capital Management
Kynam Capital Management
Perceptive Advisors
Venrock Healthcare Capital Partners
TCGX
Franklin Templeton Investments
Fidelity Investments
RTW Investments

Global footprint

Where Taysha Gene Therapies has talent and traffic

Workforce by country
🇺🇸 United States · Dallas HQ
Book a demo for the full country breakdown
Web traffic by country
14K monthly visits
across markets
🇮🇳 India52.9%
🇺🇸 United States47.1%
🇨🇦 Canada2.9%
Top 3 markets shown

Market sentiment

What the market is saying about Taysha Gene Therapies

An AI-synthesized read of the highest-engagement posts about Taysha Gene Therapies on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Taysha Gene Therapies on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles